Krebs Biochemicals & Industries Limited

CIN: L24110AP1991PLC103912



## THRU ONLINE FILING

April 7, 2023

BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 023 Scrip Code - 524518 National Stock Exchange India Limited, Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra - (East) Mumbai 400 051 Scrip Code: KREBSBIO

Dear Sir / Madam,

# Re: <u>Compliance Report on Corporate Governance for the quarter and year</u> ended March 31, 2023

Pursuant to Regulation 27(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Compliance Report (Annexure I and Annexure II) on Corporate Governance of the Company for the quarter and year ended March 31, 2023.

Kindly acknowledge receipt of the same.

Thanking you, Yours Faithfully, For Krebs Biocemicals and Industries Limited

Rohit Taparia Company Secretary & Compliance Officer

Encl: a/a



Annexure I

### FORMAT TO BE SUBMITTED BY LISTED ENTITY ON QUARTERLY BASIS

1. Name of Listed Entity: Krebs Biochemicals and Industries Limited

2. Quarter ending: March 31, 2023

|                         |   | Whether  | the listed e     | ntity has   | a Regula                | r Chairp                                   | erson                                     |                   |  |   |                                       |                                  |                      | Ye                                      | s  |  |   |  |
|-------------------------|---|--|------------------|---|-------------------------|--|---|-------------------|--|---|---------------------------------------|----------------------------------|----------------------|---|--|--|---|--|
|                         |   | Whe  | ther Chairpo     | erson is r  | elated to               | Promote                                    | ər  |                   |  |   |                                       |                                  |                      | Ye                                      | s  |  |   |  |
| Title<br>(Mr. /<br>Ms.) | Name<br>of the<br>Director                  | Category<br>(Chairperson<br>/Executive<br>/Non-<br>Executive/<br>independent/<br>Nominee)    | Date of<br>birth | Whether<br>the<br>Director<br>is<br>Disqualifi<br>ed? | date<br>of<br>Disqualif | End<br>date of<br>Disqua<br>lific<br>ation | Details<br>of<br>Disqual<br>ific<br>ation | Current<br>status | Whether<br>special<br>resolution<br>passed?<br>(Refer<br>RegIn 17<br>(1A) of<br>Listing<br>RegIn | Date of<br>passing<br>special<br>resolutio<br>n | Initial<br>Date of<br>Appoint<br>ment | Date of<br>Re-appoint<br>ment in | Date of<br>Cessation | Tenure of<br>Director<br>(in<br>months) | No of<br>Directorship<br>in listed<br>entities<br>including<br>this<br>listed entity<br>(Refer<br>Regulation<br>17A of<br>Listing<br>Regulations | Directorshi<br>in listed<br>entities<br>including<br>this listed<br>entity (Refe<br>Regulation<br>17A(1) of<br>Listing | s<br>in Audit/<br>Stakeholde<br>r<br>Committee<br>(s)<br>including<br>this<br>listed entity | No of post<br>of<br>Chairpers<br>on in<br>Audit /<br>Stakehold<br>er<br>Committe<br>e<br>held in<br>listed<br>entities<br>including<br>this<br>listed<br>entity<br>(Refer<br>Regulation<br>n<br>26(1) of<br>Listing<br>Regulations |
| Mr.                     | Ravi<br>Ravindranath<br>Tagore              | Chairperson<br>related to<br>promoter /Non-<br>Executive /<br>Non<br>Independent<br>Director | 06-08-1949       | -   | -                       | -  | -   | Active            | -  | -   | 12.10.1992                            | 13.08.2015                       | -                    | -                                       | 1  | 0  | 1   | 0  |
| Mr.                     | Avinash Ravi                                | Non-Executive /<br>Non Independent<br>Director   | 15.02.1979       | -   | -                       | -  | -   | Active            | -  | -   | 01.02.2009                            | 30.07.2021                       | -                    | -                                       | 1  | 0  | 1   | 0  |
| Mr.                     | Venkata<br>Lakshmi<br>Prasad<br>Gundapaneni | Non-Executive /<br>Independent<br>Director   | 31.07.1956       | -   | -                       | -  | -   | Active            | -  | -   | 31.12.2014                            | 25.09.2019                       | -                    | 99                                      | 1  | 1  | 0   | 2  |



| Title<br>(Mr. /<br>Ms.) | Name<br>of the<br>Director                | Category<br>(Chairperso<br>n<br>/Executive<br>/Non-<br>Executive/<br>independen<br>t/<br>Nominee) | Date of birth | Wheth<br>er<br>the<br>Direct<br>or<br>is<br>Disqu<br>alifi<br>ed? | Start<br>date<br>of<br>Disqu<br>alific<br>ation | End<br>date of<br>Disquali<br>fic<br>ation | Detail<br>s of<br>Disqu<br>alific<br>ation | Current<br>status | Whether<br>special<br>resolution<br>passed?<br>(Refer<br>RegIn 17<br>(1A) of<br>Listing<br>RegIn | Date of<br>passing<br>special<br>resolution | Initial Date<br>of<br>Appoint<br>ment | Date of<br>Re-appoint<br>ment | Date of<br>Cessation | Tenure<br>of<br>Director*<br>(in<br>months) | No of<br>Directorship<br>in listed<br>entities<br>including<br>this<br>listed entity<br>(Refer<br>Regulation<br>17A of<br>Listing<br>Regulations | No of<br>Indepen<br>dent<br>Director<br>ship<br>in listed<br>entities<br>includin<br>g this<br>listed<br>entity<br>(Refer<br>Regulati<br>on<br>17A(1)<br>of<br>Listing<br>Regulati<br>ons) | Number of<br>membershi<br>ps<br>in Audit/<br>Stakeholder<br>Committee<br>(s)<br>including<br>this<br>listed entity<br>(Refer<br>Regulation<br>26(1) of<br>Listing<br>Regulations<br>) | No of post<br>of<br>Chairpers<br>on in<br>Audit /<br>Stakehold<br>er<br>Committee<br>held in<br>listed<br>entities<br>including<br>this<br>listed<br>entity<br>(Refer<br>Regulation<br>26(1) of<br>Listing<br>Regulation<br>s) |
|-------------------------|---|---|---------------|---|---|--|--|-------------------|--|---|---------------------------------------|-------------------------------|----------------------|---|--|--|---|--|
| Mr.                     | Raj Kamal Prasad<br>Verma                 | Non-<br>Executive /<br>Independent<br>Director  | 22.03.1949    | -   | -   | -  | -  | Active            | -  | -   | 12.02.2016                            | 23.09.2021                    |                      | 85  | 3  | 3  | 2   | 2  |
| Mr.                     | Satish<br>Khemchand<br>Khivsara           | Non-<br>Executive /<br>Independent<br>Director  | 21.06.1944    | -   | -   | -  | -  | Active            | Yes  | 25.09.2019                                  | 13.08.2015                            | 25.09.2019                    |                      | 91  | 1  | 1  | 2   | 0  |
| Ms.                     | Malati Tangirala                          | Non-<br>Executive /<br>Independent<br>Director  | 04.01.1950    | -   | -   | -  | -  | Active            | -  | -   | 11.03.2015                            | 25.09.2019                    |                      | 96  | 1  | 1  | 1   | 0  |
| Mr.                     | Pabitrakumar<br>Kalipada<br>Bhattacharyya | MD /<br>Executive<br>Director   | 17.04.1969    | -   | -   | -  | -  | Active            | NA   | -   | 30.07.2021                            | 23.09.2021                    |                      | -   | 1  | 0  | 0   | 0  |
| Mr.                     | Jitendra<br>Rameshchandra<br>Shah         | Non-<br>Executive /<br>Non<br>Independent<br>Director   | 29.10.1968    | -   | -   | -  | -  | Active            | NA   | -   | 09.11.2021                            | 09.11.2021                    |                      | -   | 1  | 0  | 0   | 0  |

& Category of directors means executive/non-executive/independent/Nominee. if a director fits into more than one category write all categories separating them with hyphen

\* To be filled only for Independent Director. Tenure would mean total period from which Independent director is serving on Board of directors of the listed entity in continuity without any cooling off period.



| Name of Committee                      | Name of Committee members                 | Date of appointment<br>to the Committee | n Category<br>(Chairperson / Executive / Non-Executive / Independent / Nominee) & |
|--|---|---|---|
| 1. Audit Committee                     | Mr. Venkata Lakshmi Prasad<br>Gundapaneni | 09.11.2015                              | Chairman / Non-Executive / Independent Director                                   |
|  | Mr. Satish Khemchand<br>Khivsara          | 09.11.2015                              | Non-Executive / Independent Director  |
|  | Mrs. Malati Tangirala                     | 09.11.2015                              | Non-Executive / Independent Director  |
| 2. Nomination & Remuneration Committee | Mr. Satish Khemchand<br>Khivsara          | 09.11.2015                              | Chairman / Non-Executive / Independent Director                                   |
|  | Mr. Venkata Lakshmi Prasad<br>Gundapaneni | 09.11.2015                              | Non-Executive / Independent Director  |
|  | Mrs. Malati Tangirala                     | 09.11.2015                              | Non-Executive / Independent Director  |
|  | Mr. Ravi Ravindranath Tagore              | 09.11.2015                              | Non-Executive / Non- Independent Director   |
| 3. Stakeholders Relationship Committee | Mr. Venkata Lakshmi Prasad<br>Gundapaneni | 09.11.2015                              | Chairman / Non-Executive / Independent Director                                   |
|  | Mr. Satish Khemchand<br>Khivsara          | 09.11.2015                              | Non-Executive / Independent Director  |
|  | Mr. Ravi Ravindranath Tagore              | 09.11.2015                              | Non-Executive / Non- Independent Director   |
|  | Mr. Avinash Ravi                          | 09.11.2015                              | Non-Executive / Non- Independent Director   |

: 3:



| III. Me | eting of Board of Directors |  |   |  |   |   |
|---------|-----------------------------|--|---|--|---|---|
| Sr.     |                             | Maximum gap between any two<br>consecutive (in number of days) | Whether requirement of quorum meet (yes/No) | Total Number of Directors<br>as on date of the meeting |   | No. of Independent<br>Directors attending the<br>meeting* |
| 1.      | November 10, 2022           |  | Yes   | 8  | 7 | 3   |
| 2.      | February 03, 2023           | 10.11.2022 to 03.02.2023 – 84 days                             | Yes   | 8  | 8 | 4   |

| _      | Data(a) of monting (Enter  | Maximum gan batwaan any two                                    | Whether  | Total Number of  | Number of   | No. of  | No. of   |
|--------|--|--|--|--|---|---|--|
| Sr.    | Date(s) of meeting (Enter<br>dates of Previous quarter<br>and Current quarter in<br>chronological order) | Maximum gap between any two<br>consecutive (in number of days) | requirement of<br>quorum meet<br>(yes/No)            | Directors as on<br>date of the<br>meeting                    | Directors<br>(All directors<br>including  | Independent<br>Directors<br>attending the                       | members<br>attending the<br>meeting  |
|        |  |  |  |  | Independent<br>Director)  | meeting*  | (other than<br>Board of<br>Directors)  |
| 1.     | November 10, 2022  |  | Yes  | 3  | 2   | 2   | 0  |
| 2.     | February 03, 2023  | 10.11.2022 to 03.02.2023 – 84 days                             | Yes  | 3  | 3   | 3   | 0  |
| V. Mee | eting of Committees (Nominat   | ion and Remuneration Committee)                                | 1  |  |   | 1   | 1  |
| Sr.    | Date(s) of meeting (Enter<br>dates of Previous quarter<br>and Current quarter in<br>chronological order) | Maximum gap between any two<br>consecutive (in number of days) | Whether<br>requirement of<br>quorum meet<br>(yes/No) | Total Number of<br>Directors as on<br>date of the<br>meeting | Number of<br>Directors<br>(All directors<br>including<br>Independent<br>Director) | No. of<br>Independent<br>Directors<br>attending the<br>meeting* | No. of<br>members<br>attending the<br>meeting<br>(other than<br>Board of<br>Directors) |
| 1.     | February 03, 2023  | -  | Yes  | 4  | 4   | 3   | -  |
| VI. Me | eting of Committees (Stakeho   | Ider Relationship Committee)                                   |  |  |   |   |  |
| Sr.    | Date(s) of meeting (Enter<br>dates of Previous quarter<br>and Current quarter in<br>chronological order) | Maximum gap between any two<br>consecutive (in number of days) | Whether<br>requirement of<br>quorum meet<br>(yes/No) | Total Number of<br>Directors as on<br>date of the<br>meeting | Number of<br>Directors<br>(All directors<br>including<br>Independent<br>Director) | No. of<br>Independent<br>Directors<br>attending the<br>meeting* | No. of<br>members<br>attending the<br>meeting<br>(other than<br>Board of<br>Directors) |
| 1      | February 03, 2023  | -  | Yes  | 4  | 4   | 2   | -  |



| VIII. Related Party Transactions  |  |
|---|--|
| Subject   | Compliance status (Yes/No/N.A.) refer note below   |
| Whether prior approval of audit committee obtained  | Yes  |
| Whether shareholder approval obtained for material RPT  | Yes. Approval was obtained in the Annual General<br>Meeting of the Company held on September 30, 2022. |
| Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee  | Yes  |
| Note  |  |
| 1 In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/<br>accordance with the requirements of Listing Regulations, Yes" may be indicated. Similarly, in<br>the words "N.A." may be indicated. |  |
| 2 If status is "No" details of non-compliance may be given here.  |  |

| X. Affirmations  | Compliance Status (Y/N) |
|--|-------------------------|
| 1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.  | Yes                     |
| 2. The composition of the following committees is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015   | Yes                     |
| a. Audit Committee   | Yes                     |
| b. Nomination & remuneration committee   | Yes                     |
| c. Stakeholders relationship committee   | Yes                     |
| d. Risk management committee (applicable to the top 100 listed entities)   | NA                      |
| 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.             | Yes                     |
| 4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. | Yes                     |
| 5. This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Any comments/observations/advice of Board of Directors may be mentioned here: -  | Yes                     |
|  |                         |
| Name & Designation : Rohit Taparia, Company Secretary & Compliance Officer<br>Mumbai, April 7, 2023  |                         |

Note:

Information at Table I and II above need to be necessarily given in 1st quarter of each financial year. However if there is no change of information in subsequent quarter(s) of that financial year, this information may not be given by Listed entity and instead a statement "same as previous quarter" may be given.



### : 6 : FORMAT TO BE SUBMITTED BY LISTED ENTITY AT THE END OF THE FINANCIAL YEAR (FOR THE WHOLE OF FINANCIAL YEAR)

| Disclosure on website in terms of Listing Regulations  |  |                      |
|--|--|----------------------|
| Item   | Compliance status<br>(Yes / No / N.A.)<br>Refer note below | Web Address          |
| Details of business  | Yes  | www.krebsbiochem.com |
| Terms and conditions of appointment of independent directors   | Yes  |                      |
| Composition of various committees of board of directors  | Yes  |                      |
| Code of conduct of board of directors and senior management personnel  | Yes  |                      |
| Details of establishment of vigil mechanism / Whistle Blower policy  | Yes  | ]                    |
| Criteria of making payments to non-executive directors   | Yes  | ]                    |
| Policy on dealing with related party transactions  | Yes  | ]                    |
| Policy for determining 'material' subsidiaries   | N.A.   |                      |
| Details of familiarization programmes imparted to independent directors  | Yes  |                      |
| Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances  | Yes  |                      |
| Email address for grievance redressal and other relevant details   | Yes  |                      |
| Financial results  | Yes  | 1                    |
| Shareholding pattern   | Yes  | ]                    |
| Details of agreements entered into with the media companies and/or their associates  | N.A.   |                      |
| Schedule of analyst or institutional investor meet and presentations made<br>by the listed entity to analysts or institutional investors simultaneously with<br>submission to stock exchange | N.A.   |                      |
| New name and the old name of the listed entity   | N.A.   |                      |



| Advertisements as per regulation 47 (1)   | Yes  | www.krebsbiochem.com |
|---|------|----------------------|
| Credit rating or revision in credit rating obtained                                   | Yes  |                      |
| Separate audited financial statements of each subsidiary of the listed entity         | N.A. |                      |
| in respect of a relevant financial year   |      |                      |
| Whether company has provided information under separate section on its website as per | Yes  |                      |
| Regulation 46(2)  |      |                      |
| Materiality Policy as per Regulation 30   | Yes  |                      |
| Dividend Distribution policy as per Regulation 43A (as applicable)                    | N.A. |                      |
| It is certified that these contents on the website of the listed entity are correct   | Yes  |                      |



:8:

| Particulars   | Regulation Number      | Compliance status<br>(Yes / No / NA)<br>Refer note below |
|---|------------------------|--|
| Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility' | 16(1)(b) & 25(6)       | Yes  |
| Board composition   | 17(1), 17(1A) & 17(1B) | Yes  |
| Meeting of Board of directors   | 17(2)                  | Yes  |
| Quorum of Board meeting   | 17(2A)                 | Yes  |
| Review of Compliance Reports  | 17(3)                  | Yes  |
| Plans for orderly succession for appointments   | 17(4)                  | Yes  |
| Code of Conduct   | 17(5)                  | Yes  |
| Fees/compensation   | 17(6)                  | Yes  |
| Minimum Information   | 17(7)                  | Yes  |
| Compliance Certificate  | 17(8)                  | Yes  |
| Risk Assessment & Management  | 17(9)                  | N.A.   |
| Performance Evaluation of Independent Directors   | 17(10)                 | Yes  |
| Recommendation of Board   | 17(11)                 | Yes  |
| Maximum number of Directorships   | 17A                    | Yes  |
| Composition of Audit Committee  | 18(1)                  | Yes  |
| Meeting of Audit Committee  | 18(2)                  | Yes  |
| Composition of nomination & remuneration committee  | 19(1) & (2)            | Yes  |
| Quorum of Nomination and Remuneration Committee meeting   | 19(2A)                 | Yes  |
| Meeting of Nomination and Remuneration Committee  | 19(3A)                 | Yes  |
| Composition of Stakeholder Relationship Committee   | 20(1), 20(2) & 20(2A)  | Yes  |
| Meeting of Stakeholders Relationship Committee  | 20(3A)                 | Yes  |



| Composition and role of risk management committee   | 21(1),(2),(3),(4)            | N.A. |
|---|------------------------------|------|
| Meeting of Risk Management Committee  | 21(3A)                       | N.A. |
| Vigil Mechanism   | 22                           | Yes  |
| Policy for related party Transaction  | 23(1),(1A),(5),(6),(7) & (8) | Yes  |
| Prior or Omnibus approval of Audit Committee for all related party transactions                                   | 23(2), (3)                   | Yes  |
| Approval for material related party transactions  | 23(4)                        | Yes  |
| Disclosure of related party transactions on consolidated basis  | 23(9)                        | Yes  |
| Composition of Board of Directors of unlisted material Subsidiary   | 24(1)                        | NA   |
| Other Corporate Governance requirements with respect to subsidiary of listed entity                               | 24(2),(3),(4),(5) & (6)      | NA   |
| Annual Secretarial Compliance Report  | 24(A)                        | Yes  |
| Alternate Director to Independent Director  | 25(1)                        | NA   |
| Maximum Tenure  | 25(2)                        | Yes  |
| Meeting of independent directors  | 25(3) & (4)                  | Yes  |
| Familiarization of independent directors  | 25(7)                        | Yes  |
| Declaration from Independent Director   | 25(8) & (9)                  | Yes  |
| D & O Insurance for Independent Directors   | 25(10)                       | NA   |
| Memberships in Committees   | 26(1)                        | Yes  |
| Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel | 26(3)                        | Yes  |
| Disclosure of Shareholding by Non-Executive Directors   | 26(4)                        | Yes  |
| Policy with respect to Obligations of directors and senior management   | 26(2) & 26(5)                | Yes  |





| Sr.   | Particulars   | Compliance status (Yes/No/NA)                                   |
|-------|---|---|
| 1     | The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied  | Yes   |
| Note  | )<br>):   |   |
| W     | n the column "Compliance Status", compliance or non-compliance may be indicated by Yes / No ,<br>with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Liste<br>indicated. |   |
| 2. If | status is "No" details of non-compliance may be given here.   |   |
| 3. If | the Listed Entity would like to provide any other information the same may be indicated here.   |   |
| III A | ffirmations:  |   |
| The   | Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements   | with respect to subsidiary of Listed Entity have been complied. |
|       | Hason   |   |
|       |   |   |
|       | 2 9 Designation : Debit Tenerie, Company Secretary & Compliance Officer   |   |
| Nam   | ne & Designation : Rohit Taparia, Company Secretary & Compliance Officer  |   |



Annexure IV

### FORMAT TO BE SUBMITTED TWICE A YEAR, ON A HALF YEARLY BASIS BY THE LISTED ENTITY AT THE END OF EVERY 6 MONTHS OF THE FINANCIAL YEAR

Name of Listed Entity: Krebs Biochemicals & Industries Limited

Half year ended: March 31, 2023

I. Disclosure of Loans / guarantees / comfort letters / securities etc: - Not Applicable

There are no loans, guarantees, comfort letters or securities in connection with any loan(s) given directly or indirectly by the Company to promoter(s), promoter group, director(s), key managerial personnel or any entity controlled by them.

(A) Any loan or any other form of debt advanced by the listed entity directly or indirectly to:

|   | Aggregate<br>six months | amount advanced during | Balance outstanding at the end of six months |
|---|-------------------------|------------------------|--|
| Promoter or any other entity controlled by them                           |                         |                        |  |
| Promoter Group or any other entity controlled by them                     |                         |                        |  |
| Directors (including relatives) or any other entity controlled<br>by them |                         |                        |  |
| KMPs or any other entity controlled by them                               |                         |                        |  |



(B) Any guarantee/ comfort letter (by whatever name called) provided by the listed entity directly or indirectly connection with any loan(s) or any other form of debt availed by:

| Entity   | Type (guarantee,<br>comfort letter<br>etc.) | Aggregate amount of<br>issuance during six<br>months | Balance outstanding at the end of six months (taking into account any invocation) |
|--|---|--|---|
| Promoter or any other entity controlled by them                        |   |  |   |
| Promoter Group or any other entity controlled by them                  |   |  |   |
| Directors (including relatives) or any other entity controlled by them |   |  |   |
| KMPs or any other entity controlled by them                            |   |  |   |

(C) Any security provided by the listed entity directly or indirectly in connection with any loan(s) or any other form of debt availed by:

| Entity  | Type (guarantee,<br>comfort letter<br>etc.) | Aggregate amount of<br>issuance during six<br>months | Balance outstanding at the end of six months (taking into account any invocation) |
|---|---|--|---|
| Promoter or any other entity controlled by    |   |  |   |
| them  |   |  |   |
| Promoter Group or any other entity controlled |   |  |   |
| by them                                       |   |  |   |
| Directors (including relatives) or any other  |   |  |   |
| entity controlled by them                     |   |  |   |
| KMPs or any other entity controlled by them   |   |  |   |
|   |   |  |   |

### II. Affirmations:

All loans (or other form of debt), guarantees, comfort letters (by whatever name called) or securities in connection with any loan(s) (or other form of debt) given directly or indirectly by the listed entity to promoter(s), promoter group, director(s) (including their relatives), key managerial personnel (including their relatives) or any entity controlled by them are in the economic interest of the company. – **Not Applicable** 



#### Note

- 1. These disclosures shall exclude any loan (or other form of debt), guarantee / comfort letter (by whatever name called) or security provided in connection with any loan or any other form of debt;
  - a) by a government company to/ for the Government or government company
  - b) by the listed entity to/for its subsidiary [and joint-venture company] whose accounts are consolidated with the listed entity.
  - c) by a banking company or an insurance company ; and
  - d) by the listed entity to its employees or directors as a part of the service conditions
- 2. If the Listed Entity would like to provide any other information, the same may be indicated as Para D in the above table